blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2439212

EP2439212 - Improved fibronectin-based binding molecules and uses thereof [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  27.10.2017
Database last updated on 30.07.2024
FormerThe patent has been granted
Status updated on  18.11.2016
FormerGrant of patent is intended
Status updated on  15.11.2016
Most recent event   Tooltip15.11.2019Lapse of the patent in a contracting state
New state(s): MK		published on 18.12.2019  [2019/51]
Applicant(s)For all designated states
Novartis AG
Lichtstrasse 35
4056 Basel / CH
[2012/15]
Inventor(s)01 / Hastewell, John
Novartis Institutes for BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139 / US
02 / Loew, Andreas
Novartis Institutes for BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139 / US
 [2012/15]
Representative(s)Badur, Ralf
Novartis Pharma AG
Patent Department
4002 Basel / CH
[2016/51]
Former [2012/15]Badur, Ralf
Novartis Pharma AG Patent Department
4002 Basel / CH
Application number, filing date11191379.404.05.2009
[2012/15]
Priority number, dateUS20080050142P02.05.2008         Original published format: US 50142 P
[2012/15]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2439212
Date:11.04.2012
Language:EN
[2012/15]
Type: B1 Patent specification 
No.:EP2439212
Date:21.12.2016
Language:EN
[2016/51]
Search report(s)(Supplementary) European search report - dispatched on:EP14.03.2012
ClassificationIPC:C07K14/78, C07K16/00
[2012/15]
CPC:
C07K14/78 (EP,US); A61K47/62 (EP,US); A61P29/00 (EP);
A61P31/00 (EP); A61P35/00 (EP); A61P37/00 (EP);
A61P37/02 (EP); A61P37/06 (EP); C07K16/005 (EP,US);
C07K16/18 (EP,US); C07K16/2863 (EP,US); G01N33/6845 (US);
A61K38/00 (EP,US); C07K2317/31 (EP,US); C07K2318/20 (EP,US);
C07K2319/31 (EP,US); C07K2319/70 (EP,US); G01N2333/78 (US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2016/51]
Former [2012/15]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:Verbesserte Bindemoleküle auf Fibronectin-Basis und ihre Verwendung[2012/15]
English:Improved fibronectin-based binding molecules and uses thereof[2012/15]
French:Molécules de liaison améliorées à base de fibronectine et utilisations associées[2012/15]
Examination procedure09.10.2012Amendment by applicant (claims and/or description)
11.10.2012Examination requested  [2012/47]
08.04.2013Despatch of a communication from the examining division (Time limit: M06)
17.10.2013Reply to a communication from the examining division
24.04.2014Despatch of a communication from the examining division (Time limit: M04)
15.08.2014Reply to a communication from the examining division
06.02.2015Despatch of a communication from the examining division (Time limit: M06)
05.08.2015Reply to a communication from the examining division
17.02.2016Communication of intention to grant the patent
02.06.2016Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
07.07.2016Communication of intention to grant the patent
08.11.2016Fee for grant paid
08.11.2016Fee for publishing/printing paid
08.11.2016Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP09738252.7  / EP2274331
Divisional application(s)EP16202193.5  / EP3173424
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20090738252) is  31.07.2012
Opposition(s)22.09.2017No opposition filed within time limit [2017/48]
Fees paidRenewal fee
30.03.2012Renewal fee patent year 03
30.03.2012Renewal fee patent year 04
10.05.2013Renewal fee patent year 05
31.03.2014Renewal fee patent year 06
01.06.2015Renewal fee patent year 07
10.05.2016Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU04.05.2009
CY21.12.2016
CZ21.12.2016
DK21.12.2016
EE21.12.2016
FI21.12.2016
HR21.12.2016
LT21.12.2016
LV21.12.2016
MC21.12.2016
MK21.12.2016
RO21.12.2016
SE21.12.2016
SI21.12.2016
SK21.12.2016
BG21.03.2017
NO21.03.2017
IS21.04.2017
IE04.05.2017
LU04.05.2017
MT04.05.2017
[2019/51]
Former [2019/46]HU04.05.2009
CY21.12.2016
CZ21.12.2016
DK21.12.2016
EE21.12.2016
FI21.12.2016
HR21.12.2016
LT21.12.2016
LV21.12.2016
MC21.12.2016
RO21.12.2016
SE21.12.2016
SI21.12.2016
SK21.12.2016
BG21.03.2017
NO21.03.2017
IS21.04.2017
IE04.05.2017
LU04.05.2017
MT04.05.2017
Former [2019/31]HU04.05.2009
CZ21.12.2016
DK21.12.2016
EE21.12.2016
FI21.12.2016
HR21.12.2016
LT21.12.2016
LV21.12.2016
MC21.12.2016
RO21.12.2016
SE21.12.2016
SI21.12.2016
SK21.12.2016
BG21.03.2017
NO21.03.2017
IS21.04.2017
IE04.05.2017
LU04.05.2017
MT04.05.2017
Former [2018/43]CZ21.12.2016
DK21.12.2016
EE21.12.2016
FI21.12.2016
HR21.12.2016
LT21.12.2016
LV21.12.2016
MC21.12.2016
RO21.12.2016
SE21.12.2016
SI21.12.2016
SK21.12.2016
BG21.03.2017
NO21.03.2017
IS21.04.2017
IE04.05.2017
LU04.05.2017
MT04.05.2017
Former [2018/23]CZ21.12.2016
DK21.12.2016
EE21.12.2016
FI21.12.2016
HR21.12.2016
LT21.12.2016
LV21.12.2016
MC21.12.2016
RO21.12.2016
SE21.12.2016
SI21.12.2016
SK21.12.2016
BG21.03.2017
NO21.03.2017
IS21.04.2017
IE04.05.2017
LU04.05.2017
Former [2018/17]CZ21.12.2016
DK21.12.2016
EE21.12.2016
FI21.12.2016
HR21.12.2016
LT21.12.2016
LV21.12.2016
MC21.12.2016
RO21.12.2016
SE21.12.2016
SI21.12.2016
SK21.12.2016
BG21.03.2017
NO21.03.2017
IS21.04.2017
LU04.05.2017
Former [2018/14]CZ21.12.2016
DK21.12.2016
EE21.12.2016
FI21.12.2016
HR21.12.2016
LT21.12.2016
LV21.12.2016
MC21.12.2016
RO21.12.2016
SE21.12.2016
SI21.12.2016
SK21.12.2016
BG21.03.2017
NO21.03.2017
IS21.04.2017
LU31.05.2017
Former [2018/06]CZ21.12.2016
DK21.12.2016
EE21.12.2016
FI21.12.2016
HR21.12.2016
LT21.12.2016
LV21.12.2016
MC21.12.2016
RO21.12.2016
SE21.12.2016
SK21.12.2016
BG21.03.2017
NO21.03.2017
IS21.04.2017
LU31.05.2017
Former [2018/01]CZ21.12.2016
DK21.12.2016
EE21.12.2016
FI21.12.2016
HR21.12.2016
LT21.12.2016
LV21.12.2016
RO21.12.2016
SE21.12.2016
SK21.12.2016
BG21.03.2017
NO21.03.2017
IS21.04.2017
LU31.05.2017
Former [2017/42]CZ21.12.2016
EE21.12.2016
FI21.12.2016
HR21.12.2016
LT21.12.2016
LV21.12.2016
RO21.12.2016
SE21.12.2016
SK21.12.2016
BG21.03.2017
NO21.03.2017
IS21.04.2017
LU31.05.2017
Former [2017/35]CZ21.12.2016
EE21.12.2016
FI21.12.2016
HR21.12.2016
LT21.12.2016
LV21.12.2016
RO21.12.2016
SE21.12.2016
NO21.03.2017
Former [2017/28]FI21.12.2016
HR21.12.2016
LT21.12.2016
LV21.12.2016
SE21.12.2016
NO21.03.2017
Former [2017/12]LV21.12.2016
Documents cited:Search[X]WO0232925  (PHYLOS INC [US], et al) [X] 1-29 * page 22, lines 11-16 *;
 [X]WO0204523  (RES CORP TECHNOLOGIES INC [US], et al) [X] 1-29 * examples IV,V *;
 [X]WO03104418  (RES CORP TECHNOLOGIES INC [US], et al) [X] 1-28 * example XXI *;
 [X]  - BATORI V ET AL, "Exploring the potential of the monobody scaffold: effects of loop elongation on the stability of a fibronectin type III domain", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, (20020101), vol. 15, no. 12, ISSN 0269-2139, pages 1015 - 1020, XP002996047 [X] 1-29 * the whole document *

DOI:   http://dx.doi.org/10.1093/protein/15.12.1015
 [X]  - KOIDE AKIKO ET AL, "Probing protein conformational changes in living cells by using designer binding proteins: Application to the estrogen receptor", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (20020205), vol. 99, no. 3, ISSN 0027-8424, pages 1253 - 1258, XP009123728 [X] 1-29 * table 1 *

DOI:   http://dx.doi.org/10.1073/pnas.032665299
 [A]  - LIPOVSEK ET AL, "Evolution of an Interloop Disulfide Bond in High-Affinity Antibody Mimics Based on Fibronectin Type III Domain and Selected by Yeast Surface Display: Molecular Convergence with Single-Domain Camelid and Shark Antibodies", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, (20070417), vol. 368, no. 4, ISSN 0022-2836, pages 1024 - 1041, XP022030013 [A] 1-29 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.jmb.2007.02.029
by applicantUS6673901
 WO03104418
 US2007082365
 WO2007042289
 US5759808
 US7195880
 US6951725
 US7078197
 US7022479
 US5922545
 US5830721
 US5605793
 US5830650
 US6194550
 US6699658
 US7063943
 US5866344
 WO2006023144
 WO2005056764
 US2006286603
 WO2004041862
 US5428130
 WO9315199
 WO9315200
 EP0413622
 EP0399666
 WO0177137
 WO03006007
 US5260203
 US5455030
 US4881175
 US5132405
 US5091513
 US5476786
 US5013653
 US5258498
 US5482858
 US7045337
 US7083970
 US6927042
 EP0154316
 EP0401384
 DE19628705
 DE10129369
 US2007134197
 US2006258607
 US2006217293
 US2006100176
 US2006052342
 EP1176195
 WO03035835
 EP1297172
 US4704362
 US5741957
 US5304489
 US5849992
 US5225539
 US6180370
 US5693762
 US5693761
 US5585089
 US7022500
 US6548640
 US6982321
 US6407213
 US6639055
 US5859205
 US6632927
 US5399163
 US5383851
 US5312335
 US5064413
 US4941880
 US4790824
 US4596556
 US4487603
 US4486194
 US4447233
 US4447224
 US4439196
 US4475196
 US4522811
 US5374548
 US5399331
 US5416016
 US6524583
 US7153661
 US7119171
 US7078490
 US6703199
 US6462189
    - JOSEFINA ET AL., NATURE BIOTECHNOLOGY, (1997), vol. 15, pages 159 - 163
    - WU ET AL., NATURE BIOTECHNOLOGY, (2007), vol. 25, pages 1290 - 1297
    - BORK; DOOLITTLE, PROC. NATL. ACAD. SCI. U.S.A, (1992), vol. 89, page 8990
    - BORK ET AL., NATURE BIOTECH., (1997), vol. 15, page 553
    - MEINKE ET AL., J. BACTERIOL., (1993), vol. 175, page 1910
    - WATANABE ET AL., J. BIOL. CHEM., (1990), vol. 265, page 15659
    - CHOTHIA, C. ET AL., J. MOL. BIOL., (1987), vol. 196, pages 901 - 917
    - BIRD ET AL., SCIENCE, (1988), vol. 242, pages 423 - 426
    - HUSTON ET AL., PROC. NATL. ACAD. SCI. U.S.A, (1988), vol. 85, pages 5879 - 5883
    - KARPOVSKY ET AL., J. EXP. MED., (1984), vol. 160, page 1686
    - LIU, MA ET AL., PROC. NATL. ACAD SCI. U.S.A, (1985), vol. 82, page 8648
    - PAULUS, BEHRING INS. MITT., (1985), vol. 78, pages 118 - 132
    - BRENNAN ET AL., SCIENCE, (1985), vol. 229, pages 81 - 83
    - GLENNIE ET AL., J IMMUNOL., (1987), vol. 139, pages 2367 - 2375
    - KARPOVSKY ET AL., J EXP. MED., (1984), vol. 160, page 1686
    - LIU, MA ET AL., PROC. NATL. ACAD. SCI. US.A, (1985), vol. 82, page 8648
    - GLENNIE ET AL., J 1MMUNOL, (1987), vol. 139, pages 2367 - 2375
    - SAITO, G. ET AL., ADV. DRUG DELIV. REV., (2003), vol. 55, pages 199 - 215
    - TRAIL, P.A. ET AL., CANCER IMMUNOL. IMMUNOTHER., (2003), vol. 52, pages 328 - 337
    - PAYNE, G., CANCER CELL, (2003), vol. 3, pages 207 - 212
    - ALLEN, T.M., NAT. REV. CANCER, (2002), vol. 2, pages 750 - 763
    - PASTAN, I.; KREITMAN, R. J., CURR. OPIN. INVESTIG. DRUGS, (2002), vol. 3, pages 1089 - 1091
    - SENTER, P.D.; SPRINGER, C.J., ADV. DRUG DELIV. REV., (2001), vol. 53, pages 247 - 264
    - "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", ARNON ET AL., Monoclonal Antibodies And Cancer Therapy, ALAN R. LISS, INC., (1985), pages 243 - 256
    - "Antibodies For Drug Delivery", HELLSTROM ET AL., Controlled Drug Delivery, MARCEL DEKKER, INC., (1987), pages 623 - 653
    - "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", THORPE ET AL., Monoclonal Antibodies '84: Biological And Clinical Applications, (1985), pages 475 - 506
    - "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", Monoclonal Antibodies For Cancer Detection And Therapy, ACADEMIC PRESS, (1985), pages 303 - 316
    - THORPE ET AL., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", IMMUNOL. REV., (1982), vol. 62, doi:doi:10.1111/j.1600-065X.1982.tb00392.x, pages 119 - 158, XP001179872

DOI:   http://dx.doi.org/10.1111/j.1600-065X.1982.tb00392.x
    - BORMAN, CHEM. & ENG. NEWS, (2006), vol. 84, no. 36, pages 13 - 22
    - BORMAN, CHEM. & ENG. NEWS, (2007), vol. 85, pages 19 - 20
    - SHIELDS, R.L. ET AL., J. BIOL. CHEM., (2002), vol. 277, pages 26733 - 26740
    - CARTER ET AL., NUCLEIC ACIDS RES., (1985), vol. 13, pages 4431 - 4443
    - KUNKEL ET AL., PROC. NATL. ACAD. SCI. U.S.A, (1987), vol. 82, page 488
    - HIGUCHI, PCR Protocols, ACADEMIC PRESS, (1990), pages 177 - 183
    - VALLETTE ET AL., NUC. ACIDS RES., (1989), vol. 17, pages 723 - 733
    - WELLS ET AL., GENE, (1985), vol. 34, pages 315 - 323
    - QUEEN ET AL., IMMUNOL. REV., (1986), vol. 89, page 49
    - CO ET AL., J LMMUNOL., (1992), vol. 148, page 1149
    - CHOTHIA ET AL., J. MOL. BIOL., (1987), vol. 196, pages 901 - 917
    - MACCALLUM ET AL., J. MOL. BIOL., (1996), vol. 262, pages 732 - 745
    - BERGE, S.M. ET AL., J. PHARM. SCI., (1977), vol. 66, pages 1 - 19
    - STREJ AN ET AL., J. NEUROIMMUNOL., (1984), vol. 7, page 27
    - V.V. RANADE, J CLIN. PHARMACOL., (1989), vol. 29, page 685
    - UMEZAWA ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., (1988), vol. 153, page 1038
    - P.G. BLOEMAN ET AL., FEBS LETT., (1995), vol. 357, page 140
    - M. OWAIS ET AL., ANTIMICROB. AGENTS CHEMOTHER., (1995), vol. 39, page 180
    - BRISCOE ET AL., AM. J PHYSIOL., (1995), vol. 1233, page 134
    - SCHREIER ET AL., J BIOL. CHEM., (1994), vol. 269, page 9090
    - K. KEINANEN; M.L. LAUKKANEN, FEBS LETT., (1994), vol. 346, page 123
    - J.J. KILLION; I.J. FIDLER, LMMUNOMETHODS, (1994), vol. 4, page 273
    - CUNNINGHAM-RUNDLES C; ZHUO Z; GRIFFITH B; KEENAN J., "Biological activities of polyethylene-glycol immunoglobulin conjugates. Resistance to enzymatic degradation", J IMMUNOL METHODS, (1992), vol. 152, doi:doi:10.1016/0022-1759(92)90139-K, pages 177 - 190, XP023945030

DOI:   http://dx.doi.org/10.1016/0022-1759(92)90139-K
    - LANDOR M., "Maternal-fetal transfer of immunoglobulins", ANN ALLERGY ASTHMA IMMUNOL, (1995), vol. 74, pages 279 - 283
    - MCLEOD DS ET AL., INVEST OPHTHALMOL VIS SCI., (200202), vol. 43, no. 2, pages 474 - 482
    - WATANABE ET AL., EXP DERMATOL., (200411), vol. 13, no. 11, pages 671 - 681
    - YOSHIJI H ET AL., GUT, (200309), vol. 52, no. 9, pages 1347 - 1354
    - VERHEUL ET AL., ONCOLOGIST, (2000), vol. 5, no. 1, pages 45 - 50
    - BOLDICKE ET AL., STEM CELLS, (2001), vol. 19, no. 1, pages 24 - 36
    - LIPOVSEK, D. ET AL., J MOL BIOL., (20070511), vol. 368, no. 4, pages 1024 - 1041
    - GRÄSLUND ET AL., NATURE METHODS, (2008), vol. 5, pages 135 - 146
 WO2002EP02928
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.